BSF Enterprise

Highlighted in a recent report by Shard Capital, Cultivated Meat Technologies Limited (CMT) a subsidiary of BSF Enterprise PLC, is set to revolutionise the cultivated meat industry with a scalable, cost-effective solution that produces a premium meat product. CMT combines CellulaRevolution Ltd’s (CellRev) leading bioprocessing expertise with 3DBT’s innovative tissue engineering capabilities and the proprietary City-Mix™ supplement to create a leading end-to-end platform for premium cultivated meat production. The company is well-resourced and on track to achieve its first strategic R&D objectives within the next 18 months. With a solid foundation and the strong backing of BSF Enterprise, CMT is well-positioned to be a key player in the rapidly evolving field of cultivated food technology. Learn more about how Cultivated Meat Technologies Limited and BSF Enterprise are shaping the future of sustainable food production: https://loom.ly/SNb5O9Y #Biotechnology #CultivatedMeat #BSFEnterprise #FoodTech #InvestmentOpportunity #SustainableInnovation #CityMix

The ‘holy grail’ of lab grown leather. Shard Capital’s latest investment report highlights Lab-Grown Leather Limited (LGL), a subsidiary of BSF Enterprise, as having an innovation that is the ‘holy grail’ of lab-grown leather and positions LGL as a leader in the sustainable leather industry. The strategic goal of LGL is to establish 3D Bio-Tissues Limited (3DBT) tissue templating technology as the leading solution for sustainable leather materials, partnering with high-profile brands and key industry players to boost market penetration and credibility. The latest milestones include: ▪️ Collaboration with the ICLT at University of Northampton - Institute for Creative Leather Technologies , utilising the university's leather tanning expertise to develop ethical and sustainable leather ▪️ Establishing a collaboration with Amélie Pichard, a Paris-based fashion company known for its commitment to environmentally friendly materials ▪️ Unveiling of two bioengineered samples of 100% lab-grown leather at the Future Fabrics Expo in London LGL is now in discussions with leading fashion groups to tailor its products to their specific needs, with further updates expected in the coming months. Discover more about how Lab-Grown Leather Limited and BSF Enterprise are driving innovation in sustainable fashion and offering exciting opportunities for investors: https://loom.ly/SNb5O9Y #SustainableFashion #LabGrownLeather #BSFEnterprise #EthicalFashion #InvestmentOpportunity #Innovation

It’s great to see one of our key subsidiaries, Lab-Grown Leather Ltd, featured in World Bio Market Insights for their expansion in producing sustainable, lab-grown leather. This progress underscores our commitment to ethical, animal-free alternatives. https://loom.ly/PteetOQ

Shard Capital’s latest investment report highlights the role BSF Enterprise (Hong Kong) Ltd (BSF HK) is playing in moves to impact China’s $260 billion meat industry. As a strategic extension of BSF Enterprise PLC, BSF Enterprise (Hong Kong) Ltd (BSF HK) is focused on harnessing the opportunities within Greater China that has a 5 year agricultural plan in which cultivated meat is a key part. This year the partnership with Ivy Farm Technologies (who have raised $40m to date) strengthens the position of BSF HK for this opportunity with both companies combining strengths to make an impact on this burgeoning market. There is also a $380 billion Chinese Bio-Pharmaceutical industry that offers distribution opportunities for BSF/3DBT products. Explore how BSF HK and BSF Enterprise are at the forefront of biotechnology innovation and creating exciting opportunities for investors: https://loom.ly/SNb5O9Y #Biotechnology #CultivatedMeat #BSFEnterprise #HongKong #InvestmentOpportunity #SustainableInnovation #CityMix

Read the latest Shard Capital report on how Kerato Limited (subsidiary of BSF Enterprise PLC) is ready to access a $400 million+ cornea transplant market and the rapidly expanding $11.2 billion global in vitro toxicology testing market, Kerato is completely dedicated to going to market with two major applications: implantable medical devices and an ocular toxicity testing platform named Keratox™. This means that BSF have a route to resolving the huge deficit of implantable corneas of 12m+ people worldwide, and also to develop testing material that is biochemically equivalent to real human corneas, so that large pharma and biotech companies can perform product testing without the use of animals or human donors — a huge market need. Read the full report to see how Kerato and the other subsidiaries are shaping the future of biotechnology and creating exciting investment opportunities: https://loom.ly/SNb5O9Y #Biotechnology #CornealTreatment #KeratoLtd #BSFEnterprise #ToxicologyTesting #InvestmentOpportunity #SustainableInnovation

Shard Capital Investment Report highlights overwhelming positive feedback of key technology from 3D Bio-Tissues Limited (3DBT), a key subsidiary of BSF Enterprise PLC. 3DBT is spearheading advancements in the biotech industry with its groundbreaking tissue templating technology, which offers a no scaffold tissue approach, and globally patented, serum-free growth supplement, City-Mix™, which significantly reduces cell growth costs. These innovative technologies are fundamental to the product portfolio, supporting the various subsidiaries and making a significant step forward in responsible and sustainable biotechnology. With increased production capacity and the addition of new expertise, including the notable recruitment of Dr Chris Knowles, 3DBT is expanding its focus beyond cellular agriculture, exploring opportunities in biopharma and beyond. Read the full report to see how 3DBT and the other subsidiaries are shaping the future of biotechnology and creating exciting investment opportunities: https://loom.ly/SNb5O9Y. #Biotechnology #SustainableInnovation #3DBT #CityMix #BSFEnterprise #TissueEngineering #InvestmentOpportunity

The latest investment report by Shard Capital provides a breakdown of the growing BSF Portfolio, including 3D Bio-Tissues Limited (3DBT), Lab-Grown Leather Ltd (LGL), Kerato Ltd, BSF Enterprise (Hong Kong) Limited and Cultivated Meat Technologies (CMT) and provides clear updates on the technical and commercial progress being made by the companies across key markets within the biotech industry. BSF Enterprise PLC (BSF) has a strategy to acquire, invest, partner and develop the most promising companies from across the industry to accelerate their progress, potential and time to market. Its portfolio of subsidiaries, of which it owns 100% with the exception of 50% owned CMT, is as follows: ▪️ 3DBT - A pioneering UK-based tissue engineering company that successfully produced the UK's first high-quality cultivated meat without plant or synthetic scaffold. ▪️ Lab-Grown Leather Ltd - A company focused on the customer driven development of cultivated skin technology, producing sustainable and ethical leather with the authentic structure and genetics of real leather. ▪️ Kerato Ltd - A tissue engineering company with patent-protected IP that is already producing human corneas for testing to help restore vision to millions of people. ▪️ BSF Enterprise (Hong Kong) - Limited A company established to actively support commercialisation of BSF's technology in China and Asia. ▪️ Cultured Meat Technologies (CMT) - A 50% owned joint venture with CellulaRevolution Ltd (CellRev), focused on providing the market with the premier platform for manufacturing next generation cultivated meat in a scalable and cost-competitive manner. From developing ethical lab-grown meat and leather to advanced corneal treatments, BSF Enterprise is at the forefront of sustainable biotech innovation - working with industry-leading and global partners to achieve significant breakthroughs and bring products to market. Read the full report to see how all of these subsidiaries are shaping the future of biotechnology and creating exciting investment opportunities: https://loom.ly/SNb5O9Y #Biotechnology #SustainableInnovation #InvestInFuture #BSFEnterprise #ShardCapital #3DBT #LabGrownLeather #Kerato #CellulaRevolution #CMT

Kerato Takes Veterinary-First Approach The veterinary market is a crucial part of Kerato’s strategy to de-risk and expedite the market entry for its innovative corneal repair treatment. Initially, this will involve trials that test the new corneal treatment approach in animals before progressing to human clinical trials. This step helps to ensure the safety and efficacy of the treatment while also providing valuable data that can streamline the regulatory approval process. This approach provides animal owners with access to advanced corneal repair treatments that were previously either unavailable or prohibitively expensive. By starting with veterinary applications, Kerato will shorten the overall time required to bring the product to market. #VeterinaryTrials #AnimalHealth #CornealTreatment #TissueEngineering #Ophthalmology #AnimalCare #KeratoLtd #UniversityOfMontreal #BSFA #BSFAF

We’re excited to share that Kerato Limited's game-changing cornea tissue technology is moving to veterinary trials, thanks to a strong partnership with the Université de Montréal. It’s a proud moment for us at BSF Enterprise to see Che Connon and May Griffith team up on this groundbreaking project.

Strategic Partnership to Drive Innovation in Corneal Treatments! 🌟 BSF Enterprise PLC is pleased to announce that our subsidiary, Kerato Ltd, has entered into a strategic partnership with the University of Montreal. This collaboration aims to further develop an innovative in-situ gelling cornea, allowing the repair of tissue in the eye rather than full transplant surgery, addressing a significant unmet need in the global corneal treatment market, which is expected to grow to $767.5 million by 2030. By leveraging advanced tissue engineering, this partnership not only enhances Kerato's growth potential but also represents a strategic move to strengthen their biomedical portfolio. For more information, visit https://loom.ly/HQ7-4TI #TissueEngineering #CornealTreatment #BSFEnterprise #KeratoLtd #Innovation #UniversityOfMontreal #BSFA #BSFAF